No quarterly revenue total was found in APIMEDS PHARMACEUTICALS US, INC.'s SEC filings.
Apimeds Pharmaceuticals US, Inc. (APUS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$5.7 million. As of Jun 30, 2026 it held $278,371 in cash and investments and $161,396 in total debt.
Revenue
—
Net income
$-20.17M
-657.8% vs year-ago quarter
Operating cash flow
$-5.67M
-68.6% vs year-ago quarter
Free cash flow
$-5.67M
-67.9% vs year-ago quarter
EPS
$-11.77
-358.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.51M
-88.0% vs year-ago quarter
Net cash
$116,975
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APUS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Matawan, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1894525
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$6.3M | -$12.2M | -$7.0M | -$1.8M | -$2.7M |
| Net income | -$20.2M | -$35.1M | -$1.2M | -$1.8M | -$2.7M |
| Diluted EPS | -$11.77 | -$2.26 | -$0.09 | -$0.14 | -$2.57 |
| Operating cash flow | -$5.7M | -$2.1M | -$3.8M | -$1.7M | -$3.4M |
| Free cash flow | -$5.7M | -$2.1M | -$3.8M | -$1.7M | -$3.4M |
| Total assets | $127.6M | $141.2M | $164.2M | $9.3M | $10.5M |
| Total liabilities | $21.2M | $14.7M | $10.8M | $1.1M | $809,002 |
| Stockholders' equity | $106.4M | $126.5M | $153.3M | $8.2M | $9.7M |
| Cash and investments | $278,371 | $2.5M | $3.6M | $7.0M | $8.7M |
| Total debt | $161,396 | $171,154 | $169,032 | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Sep 23, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 21, 2026 | Aug 19, 2026 |
All 130 Apimeds Pharmaceuticals US, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.